Omeros Pivots to US Market After EU Regulatory Rejection
Healthcare providers should anticipate shifts in patient access as Omeros discontinues international compassionate-use programs.
Updated on Oct. 16, 2026 in Healthcare
Live Poll
Do you trust that pharmaceutical companies prioritize patient access in foreign markets during high domestic demand?
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a second negative opinion on the marketing authorization for narsoplimab. Omeros Corporation subsequently announced it is discontinuing its international compassionate-use program for the drug to prioritize rising demand in the United States.
Why it matters
Operators in the healthcare sector must account for the divergent regulatory paths of niche therapies, where domestic approval and reimbursement success can contrast with international market rejection. Omeros is shifting its focus toward high U.S. demand for its drug YARTEMLEA following the negative EU ruling.
Omeros reported $32.2 million in second-quarter gross revenue for YARTEMLEA, a 190% increase over the previous quarter. The company's shares are currently trading at $18.30, reflecting a 2.61% decline following the EMA's decision.
The players
Omeros Corporation
A clinical-stage biopharmaceutical company focused on the development of products for inflammation, complement-mediated diseases, and central nervous system disorders.
European Medicines Agency
The decentralized agency of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
The details
The CHMP decision followed a re-examination of an initial June rejection, supported by an eight-member ad hoc expert group that included hematologists, statisticians, and transplant physicians. While the drug remains under regulatory scrutiny in Europe, Omeros is reallocating resources to support the U.S. market, where YARTEMLEA has been approved since December 2025 and qualified for Medicare's New Technology Add-on Payment as of October 1, 2026.
Timeline
June 2026: The CHMP issued its original negative opinion for narsoplimab.
August 2026: Omeros submitted supplemental patient-level data for formal re-examination.
October 1, 2026: Medicare's New Technology Add-on Payment took effect for YARTEMLEA.
October 16, 2026: The CHMP issued a final negative opinion following the re-examination.
Market Landscape
The transition away from European markets underscores a shift toward prioritizing high-reimbursement environments like the United States. This follows the implementation of the Medicare New Technology Add-on Payment, which now serves as a key financial driver for Omeros.
Healthcare operators and pharmacy benefit managers should monitor the impact of the end of the compassionate-use program on patient access. Organizations should also track whether the shift to domestic U.S. focus affects supply chain availability for YARTEMLEA.
The takeaway
The divergence in regulatory approvals requires firms to weigh the costs of extended international advocacy against the revenue stability provided by domestic reimbursement policies. Management should track the upcoming clinical trial results for YARTEMLEA in respiratory distress to assess future market expansion potential.
What happens next
Omeros plans to launch clinical studies in acute respiratory distress syndrome and the prevention of high-risk TA-TMA in pediatric patients later this year.
Further reading
For broader trends in drug development and international regulatory environments, see Healthcare.
Live Poll
Do you trust that pharmaceutical companies prioritize patient access in foreign markets during high domestic demand?
